INTRODUCTION
Sphingolipids are degraded in the lysosomes by the sequential action of specific acid hydrolases. A mutation in one of these enzymes can result in a lack of sufficient activity to prevent accumulation of one or more substrates, and this can lead to severe clinical deterioration in a patient. The activity of these lipid hydrolases can be measured in vitro using either a synthetic substrate or a suitably labeled natural substrate usually assayed in the presence of a specific detergent. Recently, it has become evident that mammalian tissues contain proteins that act either as natural activators by binding the lipid substrates and carrying them to the specific hydrolase or as a cofactor by binding to the hydrolase to prepare it for the substrate. These include the activators of sulfatide sulfatase (1, 2) , glucosylceramide ,B-glucosidase (3), GM1 ganglioside B-galactosidase (4, 5) , GM2 ganglioside ,B-hexosaminidase A (6, 7), sphingomyelinase (8, 9) , and galactosylceramide f3-galactosidase (10) . The exact number of activator proteins is not known, and some activator proteins with different specificities appear to be identical. For example, recent studies in this laboratory (10) demonstrated that the activator protein for glucosylceramide f-glucosidase (3) may be identical to the activator of galactosylceramide ,8-galactosidase. Recently, the activator protein originally reported to activate GM1 ganglioside f-galactosidase (5) was found to be missing in cultured cells from a patient who was unable to properly metabolize sulfatide (11) . This provides evidence that the activator of GM, ganglioside may be identical to the activator of sulfatide sulfatase originally described by Mehl and Jatzkewitz (1) . This activator's exact mechanism of action and response to a defect in lysosomal function is not known.
The role that activator proteins play in the etiology of certain genetic lipidoses has only recently been elucidated. Conzelmann and Sandhoff (7) and Hechtman et al. (12) have described patients who store GM2 ganglioside because of a deficiency of the activator protein toward GM2 ganglioside f,-hexosaminidase A.
Li et al. (13) and our laboratory (14) reported that other patients who store GM2 ganglioside had normal (or elevated) levels of this activator protein and apparently normal ,3-hexosaminidase A levels (using synthetic substrates for assay). The defect in these patients appears to be in the activator protein or lipid-binding site on their f3-hexosaminidase A. Christomanou (8) reported a defect in a sphingomyelinase activator protein in some patients with juvenile Niemann-Pick disease, but this has not been confirmed. Shapiro et al. (15) reported on patients with a juvenile form of metachromatic leukodystrophy who had only partially deficient arylsulfatase A activity. Recently, our laboratory (11) demonstrated correction of in situ sulfatide metabolism in the skin fibroblasts from one of these patients by the addition of the activator protein originally demonstrated to stimulate GM, ganglioside f,-galactosidase (5) . In addition, by using monospecific antiserum to this activator protein, the patient's cultured cells were found to contain no cross-reacting material (CRM)' (11) .
It is known that the activator protein that stimulates the enzymatic hydrolysis of GM, ganglioside and sulfatide acts by binding the lipid substrates and presenting them to their specific lysosomal hydrolase (16 (5) . The purification was described in our previous communication (17) . Although the liver from the patient had about 35 times more of the activator protein than the control used, both had identical properties with regard to lipid binding, ability to stimulate only specific enzymatic reactions, and both gave only one diffuse band with Coomassie Blue staining on polyacrylamide gel electrophoresis in the presence and absence of sodium dodecyl sulfate (11, 17 The specificity of the antiserum toward this protein was determined by several criteria. Ouchterlony double immunodiffusion using the crude antiserum gave only one precipitin line with crude extracts of liver and brain. Two precipitin lines were obtained when the crude IgG fraction was used with pure activator protein and crude tissue extracts. This could reflect some denaturation of the antibodies by the treatment with ammonium sulfate as reviewed by Crowle (18) . Crossed immunoelectrophoresis (19, 20) of crude extracts of liver and brain and purified activator proteins from control and type 1 GM, gangliosidosis liver resulted in only one intense loop and one very faint loop of precipitation that ran parallel and directly under the intense loop. When the purified activator protein was preincubated with ['4C]sulfatide or ['4C]sphingomyelin before crossed immunoelectrophoresis, subsequently stained and exposed to x-ray film, the intense loop contained almost all of the radioactivity. Crude extracts of liver, brain, and cultured skin fibroblasts as well as purified activator protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis as described by Laemmli (21) . The proteins were transferred to nitrocellulose using the electrophoretic transfer method of Burnette (22) . The nitrocellulose was incubated with this antiserum, washed well, and subsequently reacted with horseradish peroxidase-goat anti-rabbit IgG. After reaction with 4-chloro-1-naphthol, multiple bands with estimated molecular weights between 8,500 and 10,000 were visualized. This agrees with our previous report of a subunit size of -10,000 (17) . Cells from the patient shown to have no CRM (11) had no visible bands by this technique. The multiple bands probably reflect different size species of the same gene product or carbohydrate chain differences. Previously, we had shown that this activator protein had two isoelectric points (17) . Rocket immunoelectrophoresis using this antiserum gave one loop of precipitation with purified activator protein and crude tissue extracts. Some slight diffusion in the precipitin line with crude extracts probably reflects a broad range for precipitation of complexes as described by Laurell (19) .
Tissue samples. Pieces of liver and brain obtained at autopsy from patients with lysosomal storage diseases and controls were frozen at -60°C until they were thawed for analysis. The liver samples from seven controls ranged in age from 2 d to 11 yr and the brain samples from four controls ranged from 4 mo to 13 yr. This covered the age range of the patients with lysosomal storage disease, except for the adult who died with type 1 Gaucher disease. The patients, with their age at death, are listed in Table I . They were diagnosed by enzyme assay and/or lipid analysis, and were categorized by their clinical presentation. The small samples (average 200 mg) were homogenized with ground glass homogenizers in 4 vol of distilled water for liver and 2 vol for brain. The homogenates were centrifuged at 20,000 g for 1 h at 4°C and the supernatant fractions were isolated. Over 85% of the protein cross-reacting with the antibodies to the activator protein was found in the supernatant fraction, as opposed to the very small amount remaining in the resuspended or detergent-extracted pellet. This was true of samples from controls and patients with lysosomal storage diseases. The protein concentration was determined according to the method of Lowry et al. (23) .
Immunological techniques. Samples of the supernatant fractions were subjected to rocket immunoelectrophoresis as described (19, 20) . Between 5 and 28 Mg of protein in 1 Ml from the extracts of liver and 5 to 15 Mg of protein in 1 Ml from the extracts of brain from patients were placed in wells in antiserum-containing gels along with known amounts of pure activator. Because of the low concentration of CRM in samples from control brain, these supernatant fractions were lyophilized and redissolved in a smaller volume of distilled water. Between 30 and 40 MAg of protein in 1 Ml was placed in the wells. After electrophoresis at 90 V for 21/2 h, the washing and staining procedures of Emmett and Crowle were followed (20) . The height of the loops from the tissue extracts were compared with the height of the loops from known amounts of pure activator protein. All extracts were initially subjected to Ouchterlony double immunodiffusion to see if any precipitin lines exhibited nonidentity with each other or the pure activator protein. Examples of double immunodiffusion are shown in Fig. 1 . In all cases the precipitin lines fused, indicating antigenic identity between liver and brain samples from patients and controls and between pure activator proteins.
Using rocket immunoelectrophoresis, the concentration of the activator protein in the liver and brain extracts was estimated. The typical patterns obtained are demonstrated on Figs. 2 and 3 . The peak heights obtained from the extracts were compared with the peak heights of known concentrations of pure activator protein. The results obtained for each sample are given in FIGURE 2 Rocket immunoelectrophoresis of extracts from liver samples and purified activator protein. All samples were applied in I-Ml aliquots and treated as described in Methods.
The initials refer to patients in Table I Gaucher disease (2 out of 3), I-Cell disease, Hurler syndrome, Hunter syndrome, and Krabbe disease (1 out of 3). Near normal levels were measured in liver samples from patients with GM2 gangliosidosis (AMB variant), type 1 Gaucher disease, type 2 Gaucher disease (1 out of 3), and Krabbe disease (2 out of 3). Liver samples from a fetus predicted and confirmed to have type A Niemann-Pick disease had a concentration more than three times above the mean for control liver and 1.6 times above the concentration measured in the liver from a fetus predicted and confirmed to have type B Niemann-Pick disease.
The results for the extracts from brain samples show an interesting pattern with the highest levels found in patients with type 1 GM1 gangliosidosis, Tay-Sachs disease, and Sandhoff disease. Significantly elevated concentrations were also found in extracts from patients with metachromatic leukodystrophy, type A NiemannPick disease, type 2 GM, gangliosidosis, Krabbe disease, and type 2 Gaucher disease (1 out of 2). Near normal concentrations were found in extracts from GM2 gangliosidosis (AMB variant), type 1 Gaucher disease, type 2 Gaucher disease (1 out of 2), and Hurler syndrome.
DISCUSSION
Using immunochemical techniques we have examined small brain and liver samples from controls and from patients with lysosomal storage disease for protein cross-reacting with antibodies to a sphingolipid activator protein. This activator protein was reported by Li and co-workers (4, 5) to activate the hydrolysis of GM, ganglioside, trihexosylceramide, and GM2 ganglioside in the presence of the specific lysosomal hydrolase. Recent studies in our laboratory (11) provide evidence that this activator protein also activates sulfatide hydrolysis by arylsulfatase A, and that at least one patient has a genetic disease caused by the lack of this activator protein. This indicates that this activator protein is identical to the one originally described by Mehl and Jatzkewitz (1) . Other studies in this laboratory have demonstrated that this activator protein binds certain sphingolipids, namely, GM1 ganglioside, GM2 ganglioside, GM3 ganglioside, sulfatide, sphingomyelin, and GAI.2 Although it has the ability to bind specific sphingolipids, it only activates the enzymatic hydrolysis of a few of these substrates in the presence of the specific hydrolase. Hydrolysis took place when GM, ,B-galactosidase was added to GAI or GM1 bound to this activator protein. The same occurred when purified arylsulfatase A was added to the sulfatide-activator complex. On the other hand, no reaction occurred when purified ,B-hexosaminidase A was added to a mixture of GM2 ganglioside and this activator protein. GM2 ganglioside can be hydrolyzed by f3-hexosaminidase A when a specific activator protein is present (6, 7) .
Antibodies to the activator protein for GM, ganglioside and sulfatide hydrolysis were raised in rabbits and they were determined to be monospecific by several criteria. There appears to be more than one form of this protein as evidenced by the finding of two isoelectric points (17) and multiple bands for the subunits on sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting. All bands are missing in the cells from the patient with a variant form of metachromatic leukodystrophy, indicating that they are probably coded for by a common gene and that our rabbit antibodies react with all of the molecular species of this protein. These antibodies gave only one loop of precipitation on rocket immunoelectrophoresis of all samples and therefore they could be used to estimate the concentration of CRM in small tissue samples.
The finding of an extremely high concentration of activator protein in the livers of patients with type 1 GM, gangliosidosis agrees with our previous study, which required large tissue samples and time-consuming purification (17) ( 
